Incyte (INCY) Stock Price, News & Analysis

Incyte logo
$119.09 -1.18 (-0.98%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$114.75 -4.34 (-3.64%)
As of 09:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Incyte Stock (NASDAQ:INCY)

Advanced

Key Stats

Today's Range
$118.05
▼
$121.43
50-Day Range
$108.62
▼
$127.62
52-Week Range
$89.25
▼
$132.60
Volume
2.25 million shs
Average Volume
1.77 million shs
Market Capitalization
$24.27 billion
P/E Ratio
63.35
Dividend Yield
N/A
Price Target
$133.86
Consensus Rating
Hold

Company Overview

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally.

Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions. Incyte also markets medicines including Pemazyre for certain cancers and Monjuvi in the United States, in partnership with MorphoSys, for a type of lymphoma.

Incyte continues to develop medicines across its therapeutic areas through internal research and collaborations. Hervé Hoppenot serves as the company’s chief executive officer.

AI Generated. May Contain Errors.

Incyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

INCY MarketRank™: 
3.048260231965 of 5 stars

Incyte scored higher than 61% of companies evaluated by MarketBeat, and ranked 369th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Incyte has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 11 buy ratings, 14 hold ratings, and no sell ratings.

  • Upside Potential

    Incyte has a consensus price target of $133.86, representing about 12.4% upside from its current price of $119.09.

  • Amount of Analyst Coverage

    Incyte has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Incyte's stock forecast and price target.
  • Earnings Growth

    Earnings for Incyte are expected to grow by 254.02% in the coming year, from $2.24 to $7.93 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Incyte is 63.35, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.23.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Incyte is 63.35, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.31.

  • Price to Earnings Growth Ratio

    Incyte has a PEG Ratio of 4.38. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Incyte has a P/B Ratio of 4.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.23% of the float of Incyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Incyte has a short interest ratio ("days to cover") of 5.58.
  • Change versus previous month

    Short interest in Incyte has recently increased by 6.22%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Incyte does not currently pay a dividend.

  • Dividend Growth

    Incyte does not have a long track record of dividend growth.

  • News Sentiment

    Incyte has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Incyte this week, compared to 9 articles on an average week.
  • Search Interest

    22 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 16% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,455,017.00 in company stock.

  • Percentage Held by Insiders

    16.20% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Incyte's insider trading history.
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INCY Stock News Headlines

Piper Sandler Remains a Buy on Incyte (INCY)
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Incyte (NASDAQ:INCY) CMO Sells $28,436,449.27 in Stock
Incyte (NASDAQ:INCY) Insider Sells $72,565.60 in Stock
See More Headlines

INCY Stock Analysis - Frequently Asked Questions

Incyte's stock was trading at $98.77 at the start of the year. Since then, INCY stock has increased by 20.6% and is now trading at $119.09.

Incyte Corporation (NASDAQ:INCY) announced its quarterly earnings data on Thursday, October, 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping the consensus estimate of ($3.93) by $0.33. The firm's revenue was up 14.0% on a year-over-year basis.
Read the conference call transcript
.

Top institutional shareholders of Incyte include Baker BROS. Advisors LP (15.09%), Dodge & Cox (4.94%), State Street Corp (4.84%) and Robeco Institutional Asset Management B.V. (1.09%). Insiders that own company stock include Pablo J Cagnoni, Mohamed Khairie Issa, Patrick A Mayes, Barry P Flannelly, Jonathan Elliott Dickinson, Vijay K Iyengar, Steven H Stein, Michael James Morrissey, Lee Heeson, Sheila A Denton and Thomas Tray.
View institutional ownership trends
.

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Alibaba Group (BABA) and Tesla (TSLA).

Company Calendar

Last Earnings
10/29/2026
Today
11/18/2026
Investor update
12/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INCY
CIK
879169
Employees
2,844
Year Founded
1991

Price Target and Rating

High Price Target
$157.00
Low Price Target
$90.00
Potential Upside/Downside
+12.4%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
25 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.88
Trailing P/E Ratio
63.35
Forward P/E Ratio
15.02
P/E Growth
4.38
Net Income
$1.29 billion
Net Margins
6.71%
Pretax Margin
13.25%
Return on Equity
7.92%
Return on Assets
6.12%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.84
Quick Ratio
3.75

Sales & Book Value

Annual Sales
$5.14 billion
Price / Sales
4.72
Cash Flow
$6.12 per share
Price / Cash Flow
19.46
Book Value
$27.68 per share
Price / Book
4.30

Miscellaneous

Outstanding Shares
203,830,000
Free Float
170,811,000
Market Cap
$24.27 billion
Optionable
Optionable
Beta
0.78

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:INCY) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners